However, the treatment of breast cancer cell lines with Vorapaxar inhibited migration and invasion in vitro [151], while in pancreatic cancer, PAR1 signalling was shown to mediate hypercoagulation and immune escape [152]; therefore, PAR-1 inhibitors could play an important therapeutic role in this tumour by mediating different aspects of tumour progression. This evidence concerns the gene F2R and familial pancreatic carcinoma.